SG11202109522VA - Aromatic derivatives, preparation methods, and medical uses thereof - Google Patents

Aromatic derivatives, preparation methods, and medical uses thereof

Info

Publication number
SG11202109522VA
SG11202109522VA SG11202109522VA SG11202109522VA SG11202109522VA SG 11202109522V A SG11202109522V A SG 11202109522VA SG 11202109522V A SG11202109522V A SG 11202109522VA SG 11202109522V A SG11202109522V A SG 11202109522VA SG 11202109522V A SG11202109522V A SG 11202109522VA
Authority
SG
Singapore
Prior art keywords
preparation methods
medical uses
aromatic derivatives
aromatic
derivatives
Prior art date
Application number
SG11202109522VA
Other languages
English (en)
Inventor
Ning Shao
Hongbin Yuan
Ding Wang
Frank Kayser
Original Assignee
Bioardis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioardis Llc filed Critical Bioardis Llc
Publication of SG11202109522VA publication Critical patent/SG11202109522VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SG11202109522VA 2019-03-05 2020-02-19 Aromatic derivatives, preparation methods, and medical uses thereof SG11202109522VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2019/076926 WO2020177067A1 (en) 2019-03-05 2019-03-05 Aromatic derivatives, preparation methods, and medical uses thereof
PCT/CN2020/075849 WO2020177534A1 (en) 2019-03-05 2020-02-19 Aromatic derivatives, preparation methods, and medical uses thereof

Publications (1)

Publication Number Publication Date
SG11202109522VA true SG11202109522VA (en) 2021-09-29

Family

ID=72337401

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202109522VA SG11202109522VA (en) 2019-03-05 2020-02-19 Aromatic derivatives, preparation methods, and medical uses thereof

Country Status (10)

Country Link
US (1) US11976058B2 (cg-RX-API-DMAC7.html)
EP (1) EP3935048A4 (cg-RX-API-DMAC7.html)
JP (1) JP7470708B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210135558A (cg-RX-API-DMAC7.html)
CN (1) CN111902400B (cg-RX-API-DMAC7.html)
CA (1) CA3132405A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021552133A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109522VA (cg-RX-API-DMAC7.html)
TW (1) TWI860334B (cg-RX-API-DMAC7.html)
WO (2) WO2020177067A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12595370B2 (en) 2018-03-02 2026-04-07 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
US10935695B2 (en) 2018-03-02 2021-03-02 Johnson & Johnson Vision Care, Inc. Polymerizable absorbers of UV and high energy visible light
US12595371B2 (en) 2018-03-02 2026-04-07 Johnson & Johnson Vision Care, Inc. Contact lens with improved vision break-up time
US12674032B2 (en) 2019-06-28 2026-07-07 Johnson & Johnson Vision Care, Inc. Polymerizable fused tricyclic compounds as absorbers of UV and visible light
US20220194944A1 (en) * 2020-12-18 2022-06-23 Johnson & Johnson Vision Care, Inc. Photostable mimics of macular pigment

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012271357A1 (en) 2011-06-16 2013-05-02 Ionis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
NZ703495A (en) * 2012-07-11 2018-02-23 Blueprint Medicines Corp Inhibitors of the fibroblast growth factor receptor
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Fgfr阻害剤耐性癌の治療薬
SG11201602069WA (en) 2013-10-18 2016-04-28 Eisai R&D Man Co Ltd Pyrimidine fgfr4 inhibitors
PT3395814T (pt) 2013-10-25 2022-07-27 Blueprint Medicines Corp Inibidores do recetor do fator de crescimento de fibroblastos
CN105683188B (zh) 2013-10-25 2018-02-09 诺华股份有限公司 作为fgfr4抑制剂的稠环二环吡啶基衍生物
WO2015108992A1 (en) * 2014-01-15 2015-07-23 Blueprint Medicines Corporation Heterobicyclic compounds and their use as fgfr4 receptor inhibitors
MA38393B1 (fr) 2014-03-13 2018-11-30 Sanofi Sa Composés hétéroaryle et utilisations associées
JP6655559B2 (ja) 2014-06-24 2020-02-26 コベストロ、ドイチュラント、アクチエンゲゼルシャフトCovestro Deutschland Ag ジフェニルメタン系ジアミンおよびポリアミンの製造方法
WO2016064960A1 (en) * 2014-10-22 2016-04-28 Incyte Corporation Bicyclic heterocycles as fgfr4 inhibitors
EP3029864B1 (en) 2014-12-01 2020-11-18 Harman Becker Automotive Systems GmbH Fast representation of station information in a fm receiver using a single tuner
CA2976790C (en) 2015-02-20 2024-02-27 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
US9580423B2 (en) * 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
CN105906630B (zh) 2015-04-06 2018-10-23 四川百利药业有限责任公司 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物
WO2016164703A1 (en) 2015-04-09 2016-10-13 Eisai R & D Management Co., Ltd. Fgfr4 inhibitors
CN107286130A (zh) * 2016-04-13 2017-10-24 成都融科博海科技有限公司 一种激酶选择性抑制剂
RU2747260C2 (ru) * 2016-12-19 2021-04-29 Аббиско Тхерапеутицс Цо., Лтд. Ингибитор рфрф4, способ его получения и его фармацевтическое применение
CN110997637B (zh) * 2017-09-05 2022-09-27 保仕健生物科技(上海)有限公司 芳香类衍生物、其制备方法及其在医药上的应用
CN109224235B (zh) 2018-10-23 2020-05-19 孙喜家 一种双腔管
CN109331654A (zh) 2018-10-26 2019-02-15 高邮高和光电器材有限公司 一种有机废气光催化氧化装置

Also Published As

Publication number Publication date
WO2020177067A1 (en) 2020-09-10
US20220169634A1 (en) 2022-06-02
CN111902400A (zh) 2020-11-06
US11976058B2 (en) 2024-05-07
WO2020177534A1 (en) 2020-09-10
PH12021552133A1 (en) 2022-08-22
CA3132405A1 (en) 2020-09-10
EP3935048A1 (en) 2022-01-12
EP3935048A4 (en) 2022-11-09
KR20210135558A (ko) 2021-11-15
TWI860334B (zh) 2024-11-01
JP2022522890A (ja) 2022-04-20
TW202100514A (zh) 2021-01-01
CN111902400B (zh) 2024-08-30
JP7470708B2 (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
EP3733715A4 (en) TRIABODY, THE METHOD FOR ITS MANUFACTURING AND ITS USE
EP3907218A4 (en) 6-OXO-1,6-DIHYDROPYRIDAZINE DERIVATIVE, METHOD FOR PREPARATION AND MEDICAL USE
PT3546457T (pt) Derivado de pirazolo-heteroarílico, método de preparação e a utilização médica do mesmo
EP3636646A4 (en) HETEROARYL PYRAZOL DERIVATIVE AND MANUFACTURING METHOD FOR IT AND MEDICAL USES THEREOF
EP3248963A4 (en) Pyrrole sulfonyl derivative, and preparation method and medical use thereof
ZA201900470B (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EP4023659A4 (en) COMPOUND AND DRUG CONJUGATE, PRODUCTION METHOD AND USE THEREOF
EP3378859A4 (en) Benzofuran derivative, preparation method thereof and use thereof in medicine
EP3919489A4 (en) AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND MEDICAL USE
EP3261501A4 (en) Soft, strong and bulky tissue
EP3935048A4 (en) AROMATIC DERIVATIVES, PROCESSES FOR THE PREPARATION AND MEDICAL USES THEREOF
EP3569596A4 (en) 1,2,4-TRIAZINE-3-AMINE DERIVATIVE, PROCESS OF PREPARATION AND USE IN MEDICINE
EP3251698A4 (en) Ligand-cytotoxicity drug conjugate, preparing method therefor, and application thereof
EP3395809A4 (en) BENZOPIPERIDIN DERIVATIVE, PRODUCTION METHOD AND MEDICAL USE THEREOF
EP3287461A4 (en) Imidazo isoindole derivative, preparation method therefor and medical use thereof
IL276952A (en) History of 4,2-diaminoquinazolines and their medicinal uses
IL272446A (en) Penta-condensed hexa-heterocyclic compounds, method for their preparation, drug combination and use thereof
EP3527552A4 (en) CONDENSED TRICYCLIC µ-AMINO ACID DERIVATIVE, PRODUCTION METHOD THEREFOR AND MEDICAL USE THEREOF
EP3699179A4 (en) TRICYCLIC DERIVATIVE CONTAINING PYRAZOLYL, PROCESS FOR PREPARATION AND USE
SG11202103951VA (en) Phenol derivative, and preparation process and use thereof
EP3281527A4 (en) Antimicrobial traditional chinese medicine composition, and preparation method and use thereof
SG11202004292PA (en) Medicine for tissue regeneration, and preparation method therefor
SG11202007521PA (en) Urea-substituted aromatic ring-linked dioxazoline compound, preparation method therefor, and uses thereof
EP3647437A4 (en) NANOVESICLE DERIVED FROM BACTERIA OF THE PROTEUS GENUS AND ITS USE
EP3950693A4 (en) THIENOHETEROCYCLIC DERIVATIVE, METHOD FOR PREPARING IT AND ITS MEDICAL USE